primary membranous nephropathy (MN) and IgA nephropathy (IgAN)
Conditions
Interventions
membrane nephrapathy group:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 years or older; 2. Patients diagnosed with primary membranous nephropathy according to the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases; 3. Serum anti-PLA2R antibody positive; 4. No previous treatment with rituximab or calcineurin inhibitors (such as cyclosporine, tacrolimus), and no prior use of novel drugs specifically for MN; 5. If previously treated with glucocorticoids or alkylating agents, discontinuation for at least 6 months is required.
Exclusion criteria
Exclusion criteria: 1. Secondary MN clearly caused by other etiologies such as lupus, hepatitis, malignancy, or drugs. 2. Previous treatment with rituximab or calcineurin inhibitors (e.g., cyclosporine, tacrolimus), or receipt of novel drugs for MN. 3. Severe renal impairment: estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m² (calculated using the MDRD formula). 4. Uncontrolled hypertension. 5. Active infection (including hepatitis B, hepatitis C, HIV). 6. Presence of other severe or unstable illnesses. 7. Neutropenia (neutrophil count < 1.5 x 10³/µL). 8. Thrombocytopenia (platelet count < 100,000/µL). 9. Any hematologic disorder, or disease affecting the hematopoietic system. 10. Current or prior (within six months before enrollment) use of drugs affecting the immune or hematopoietic system. 11. Pregnancy or lactation. 12. Patients of childbearing potential unwilling to use effective contraception during the study period. 13. Other populations deemed ineligible by the investigator or ethics committee.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene; | — |
Countries
China
Contacts
Public ContactZibo Xiong
Peking University Shenzhen Hospital
Outcome results
None listed